SCHEMBL1026474

SCHEMBL1026474

Cc1cc(N2CCOCC2)c(C#Cc2cccc(N)c2)cc1NC(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
POLB P06746 2/20 0.40
SCN9A Q15858 1/20 0.40
PKM P14618 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 1/20 0.39
ATM Q13315 1/20 0.39
HPGD P15428 1/20 0.39
ABL1 P00519 1/20 0.39
CSF1R P07333 1/20 0.39
BCR P11274 1/20 0.39
SRC P12931 1/20 0.39
BRAF P15056 1/20 0.39
FLT3 P36888 1/20 0.39
KCNH2 Q12809 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13622522 0.89 ALDH1A1 (0.39) ALDH1A1KMT2AMEN1POLBPKM
SCHEMBL7702830 0.80 NPC1 (0.45) ALDH1A1KMT2AMEN1POLBSCN9A
SCHEMBL1023637 0.76 KMT2A (0.46) ALDH1A1KMT2AMEN1SCN9APKM
SCHEMBL1075283 0.76 PDE2A (0.39) TSHRHPGDABL1CSF1RBCR
SCHEMBL7700573 0.73 ALDH1A1 (0.53) ALDH1A1KMT2AMEN1POLBPKM
SCHEMBL1024266 0.71 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1POLBPKM
SCHEMBL1025212 0.71 MAPT (0.52) ALDH1A1KMT2AMEN1POLBLMNA
SCHEMBL7139847 0.71 PRKDC (0.41) ALDH1A1KMT2AMEN1POLBSCN9A
SCHEMBL1025211 0.71 MAPT (0.52) ALDH1A1KMT2AMEN1POLBLMNA
SCHEMBL4326786 0.69 ALDH1A1 (0.70) ALDH1A1KMT2AMEN1POLBSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALDH1A1 2511/4885KMT2A 382/4885MEN1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.